Over the past five decades, targeted therapies—such as those aimed at FLT3[2] and IDH1 mutations[3] have broadened the therapeutic armamentarium in AML and yielded demonstrable improvements in patient survival. The gene discussed is FLT3; the disease is acute myeloid leukemia.